Literature DB >> 29631357

Loss of biliverdin reductase-A promotes lipid accumulation and lipotoxicity in mouse proximal tubule cells.

Samuel O Adeosun1, Darren M Gordon2, Mary Frances Weeks1, Kyle H Moore1, John E Hall1, Terry D Hinds2, David E Stec1.   

Abstract

Obesity and increased lipid availability have been implicated in the development and progression of chronic kidney disease. One of the major sites of renal lipid accumulation is in the proximal tubule cells of the kidney, suggesting that these cells may be susceptible to lipotoxicity. We previously demonstrated that loss of hepatic biliverdin reductase A (BVRA) causes fat accumulation in livers of mice on a high-fat diet. To determine the role of BVRA in mouse proximal tubule cells, we generated a CRISPR targeting BVRA for a knockout in mouse proximal tubule cells (BVRA KO). The BVRA KO cells had significantly less metabolic potential and mitochondrial respiration, which was exacerbated by treatment with palmitic acid, a saturated fatty acid. The BVRA KO cells also showed increased intracellular triglycerides which were associated with higher fatty acid uptake gene cluster of differentiation 36 as well as increased de novo lipogenesis as measured by higher neutral lipids. Additionally, neutrophil gelatinase-associated lipocalin 1 expression, annexin-V FITC staining, and lactate dehydrogenase assays all demonstrated that BVRA KO cells are more sensitive to palmitic acid-induced lipotoxicity than wild-type cells. Phosphorylation of BAD which plays a role in cell survival pathways, was significantly reduced in palmitic acid-treated BVRA KO cells. These data demonstrate the protective role of BVRA in proximal tubule cells against saturated fatty acid-induced lipotoxicity and suggest that activating BVRA could provide a benefit in protecting from obesity-induced kidney injury.

Entities:  

Keywords:  CRISPR; apoptosis; bilirubin; kidney; obesity; palmitic acid

Mesh:

Substances:

Year:  2018        PMID: 29631357      PMCID: PMC6139518          DOI: 10.1152/ajprenal.00495.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  46 in total

1.  Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease.

Authors:  Yu-Cheng Lin; Pi-Feng Chang; Fu-Chang Hu; Mei-Hwei Chang; Yen-Hsuan Ni
Journal:  Pediatrics       Date:  2009-12       Impact factor: 7.124

2.  Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

Authors:  J Zha; H Harada; E Yang; J Jockel; S J Korsmeyer
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

3.  Lipotoxicity in renal proximal tubular cells: relationship between endoplasmic reticulum stress and oxidative stress pathways.

Authors:  Elias Katsoulieris; Jon G Mabley; Mohamed Samai; Martyn A Sharpe; Irene C Green; Prabal K Chatterjee
Journal:  Free Radic Biol Med       Date:  2010-04-02       Impact factor: 7.376

4.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

Authors:  L del Peso; M González-García; C Page; R Herrera; G Nuñez
Journal:  Science       Date:  1997-10-24       Impact factor: 47.728

5.  Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease.

Authors:  Davide Bolignano; Giuseppe Coppolino; Susanna Campo; Carmela Aloisi; Giacomo Nicocia; Nicola Frisina; Michele Buemi
Journal:  Am J Nephrol       Date:  2007-06-13       Impact factor: 3.754

6.  Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity.

Authors:  Jaya Mishra; Kiyoshi Mori; Qing Ma; Caitlin Kelly; Jonathan Barasch; Prasad Devarajan
Journal:  Am J Nephrol       Date:  2004-05-12       Impact factor: 3.754

7.  Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy.

Authors:  Katalin Susztak; Emilio Ciccone; Peter McCue; Kumar Sharma; Erwin P Böttinger
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

8.  Relationship between Serum Bilirubin Levels and Metabolic Syndrome in Patients with Schizophrenia Spectrum Disorders.

Authors:  Filiz Karadag; Ceyhan Balci Sengul; Yasar Enli; Kamuran Karakulah; Huseyin Alacam; Bunyamin Kaptanoglu; Ozgur Kalkanci; Hasan Herken
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-05-31       Impact factor: 2.582

9.  Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease.

Authors:  Min-Sun Kwak; Donghee Kim; Goh Eun Chung; Seung Joo Kang; Min Jung Park; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  Clin Mol Hepatol       Date:  2012-12-21

10.  Renal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in Podocytes.

Authors:  Cristina Martínez-García; Adriana Izquierdo-Lahuerta; Yurena Vivas; Ismael Velasco; Tet-Kin Yeo; Sheldon Chen; Gema Medina-Gomez
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

View more
  23 in total

1.  A Simple and Cost Effective Turn off Fluorescence Sensor for Biliverdin and Bilirubin Based on L-Cysteine Modulated Copper Nanoclusters.

Authors:  Sanu K Anand; Manna Rachel Mathew; K Girish Kumar
Journal:  J Fluoresc       Date:  2019-12-19       Impact factor: 2.217

2.  Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.

Authors:  David E Stec; Darren M Gordon; Jennifer A Hipp; Stephen Hong; Zachary L Mitchell; Natalia R Franco; J Walker Robison; Christopher D Anderson; Donald F Stec; Terry D Hinds
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-09-04       Impact factor: 3.619

3.  Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor α.

Authors:  Darren M Gordon; Kari L Neifer; Abdul-Rizaq Ali Hamoud; Charles F Hawk; Andrea L Nestor-Kalinoski; Scott A Miruzzi; Michael P Morran; Samuel O Adeosun; Jeffrey G Sarver; Paul W Erhardt; Robert E McCullumsmith; David E Stec; Terry D Hinds
Journal:  J Biol Chem       Date:  2020-05-13       Impact factor: 5.157

4.  RNA sequencing in human HepG2 hepatocytes reveals PPAR-α mediates transcriptome responsiveness of bilirubin.

Authors:  Darren M Gordon; Thomas M Blomquist; Scott A Miruzzi; Robert McCullumsmith; David E Stec; Terry D Hinds
Journal:  Physiol Genomics       Date:  2019-05-10       Impact factor: 3.107

Review 5.  Bilirubin Safeguards Cardiorenal and Metabolic Diseases: a Protective Role in Health.

Authors:  Terry D Hinds; David E Stec
Journal:  Curr Hypertens Rep       Date:  2019-10-10       Impact factor: 5.369

6.  Deletion of Biliverdin Reductase A in Myeloid Cells Promotes Chemokine Expression and Chemotaxis in Part via a Complement C5a--C5aR1 Pathway.

Authors:  Kavita Bisht; Giacomo Canesin; Tasneem Cheytan; Mailin Li; Zsuzsanna Nemeth; Eva Csizmadia; Trent M Woodruff; David E Stec; Andrew C Bulmer; Leo E Otterbein; Barbara Wegiel
Journal:  J Immunol       Date:  2019-04-05       Impact factor: 5.422

Review 7.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

Review 8.  Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases.

Authors:  David E Stec; Claudio Tiribelli; Olufunto O Badmus; Terry D Hinds
Journal:  Kidney360       Date:  2022-03-25

Review 9.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

Review 10.  Bilirubin as a metabolic hormone: the physiological relevance of low levels.

Authors:  Justin F Creeden; Darren M Gordon; David E Stec; Terry D Hinds
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-07       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.